Biomed 344
Latest Information Update: 16 Jul 2016
At a glance
- Originator Intarcia Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 01 Oct 2004 BioMedicines is now called Intarcia Therapeutics
- 14 Oct 2002 Preclinical trials in Solid tumours in USA (unspecified route)